Location of Repository

Protein Engineering of P450BM3 by Rational Redesign

By Wei-Cheng Huang


The potential of flavocytochrome P450BM3 (CYP102A1) from Bacillus megaterium for\ud industrial chemical transformation and biotechnological application is widely acknowledged. The crystal structures of P450BM3 with fatty acid substrates bound present non-productive modes of binding of substrate with their carbons distant from the iron and the ω-terminal end in a\ud hydrophobic pocket at one side of the active site. Comparison between substrate-free and\ud substrate-bound structures of P450BM3 revealed two pockets (A-arm and B-arm) in the\ud substrate binding channel. In this thesis, A82(I/F/W) mutants in which the ‘B-arm’ pocket is filled by large hydrophobic side chains at position 82 were constructed and characterised. The A82F and A82W mutants have greater affinities for substrates (~ 800-fold) as well as being more effective catalysts of indole hydroxylation than the wild-type enzyme. The crystal structure of\ud the haem domain of the A82F mutant with bound palmitate showed different substrate binding position, in which the substrate is closer to the haem iron than wild-type enzyme. On this basis, a second series of mutants with substitutions at position 438 as well as 82, in which the ‘A-arm’ pocket is modulated by large hydrophobic side chains, were constructed and characterised. The hydroxylation of 11-methyllaurate by wild-type was found to yield traces of the ω-hydroxylated product, which is the first observation of ω-hydroxylase activity of wild-type P450BM3 to date. The mutants with both ‘B-arm’ pocket and ‘A-arm’ pocket filled with larger hydrophobic residues (A82F-T438(V/I/L/F) mutants) demonstrated 2- to 3-fold increases in the formation of\ud ω-hydroxyl-11-methyllaurate. Notably, the A82F-T438L and A82F-T438F mutants also\ud presented a marked enhancement of stereo-selectivity for styrene epoxidation to generate R-styrene oxide (~ 30-fold), suggesting that not only that these mutants of P450BM3 will be valuable catalysts for synthetically useful hydroxylation reactions but also that structure-based rational redesign will be one of the most efficient tools to generate novel biocatalysts

Publisher: University of Leicester
Year: 2008
OAI identifier: oai:lra.le.ac.uk:2381/8457

Suggested articles



  1. (2004). 4-cyanopyridine, a versatile spectroscopic probe for cytochrome P450 BM3.
  2. (1999). A continuous spectrophotometric assay for P450 BM-3, a fatty acid hydroxylating enzyme, and its mutant F87A.
  3. (2003). A graphical user interface to the CCP4 program suite. Acta Crystallographica. Section D:
  4. (2003). A method for determining two substrates binding in the same active site of cytochrome P450BM3: an explanation of high energy ω product formation.
  5. (2000). A model "rebound" mechanism of hydroxylation by cytochrome P450: stepwise and effectively concerted pathways, and their reactivity patterns.
  6. (1996). A model for human cytochrome P450 2D6 based on homology modeling and NMR studies of substrate binding.
  7. (2002). A new test set for validating predictions of protein-ligand interaction.
  8. (2002). A novel sterol 14alpha-demethylase/ferredoxin fusion protein (MCCYP51FX) from Methylococcus capsulatus represents a new class of the cytochrome P450 superfamily.
  9. (2001). A P450 BM-3 mutant hydroxylates alkanes, cycloalkanes, arenes and heteroarenes.
  10. (2005). A review of antioxidants and Alzheimer's disease.
  11. (2006). A role for the strained phenylalanine ring rotation induced by substrate
  12. (2006). A screening system for the directed evolution of epoxygenases: Importance of position 184 in P450 BM3 for stereoselective styrene epoxidation.
  13. (2003). A self-sufficient cytochrome P450 with a primary structural organization that includes a flavin domain and a [2Fe-2S] redox center.
  14. (1997). A single mutation in cytochrome P450 BM3 changes substrate orientation in a catalytic intermediate and the regiospecificity of hydroxylation.
  15. (2004). A single mutation in cytochrome P450 BM3 induces the conformational rearrangement seen upon substrate binding in the wild-type enzyme.
  16. (2006). A statistical analysis of random mutagenesis methods used for directed protein evolution.
  17. (2003). A theoretical study on the mechanism of camphor hydroxylation by compound I of cytochrome P450.
  18. (1995). A three-dimensional model of aromatase cytochrome P450.
  19. (2005). Acetyl-L-carnitine improves pain, Protein Engineering Of P450BM3 By Rational Redesign - 195 -nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials.
  20. (2000). Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression.
  21. (2005). Activation of molecular oxygen by cytochrome P450. IN
  22. (2006). Active site mutations of P450BM-3 that dramatically affect substrate binding and product formation.
  23. (2004). Alkene epoxidation catalyzed by cytochrome P450 BM-3 139-3.
  24. (1998). All-atom empirical potential for molecular modeling and dynamics studies of proteins.
  25. (1997). An active site substitution, F87V, converts cytochrome P450 BM-3 into a regio- and stereoselective (14S,15R)-arachidonic acid epoxygenase.
  26. (1994). An NMR-derived model for the solution structure of oxidized putidaredoxin, a 2-Fe, 2-S ferredoxin from Protein Engineering Of P450BM3 By Rational Redesign - 192 -Pseudomonas.
  27. (1999). An unusual matrix of stereocomplementarity in the hydroxylation of monohydroxy fatty acids catalysed by cytochrome P450 from Bacillus megaterium with potential application in biotransformations.
  28. (2005). Analysis of coumarin 7-hydroxylation activity of cytochrome P450 2A6 using random mutagenesis.
  29. and properties.
  30. (2006). Are branched chain fatty acids the natural substrates for P450BM3? Chemical Communications
  31. (2007). Are transversion mutations better? A mutagenesis assistant program analysis on P450 BM-3 heme domain.
  32. (2004). Biochemical characterization of StyAB from Pseudomonas sp. strain VLB120 as a two-component Protein Engineering Of P450BM3 By Rational Redesign - 191 -flavin-diffusible monooxygenase.
  33. (2005). Biotransformation of β-ionone by engineered cytochrome P450 BM-3.
  34. (2002). Biotransformations using prokaryotic P450 monooxygenases.
  35. (1977). Characteristics of a cytochrome P-450-dependent fatty acid ω-2 hydroxylase from Bacillus megaterium.
  36. (1986). Characterization of a catalytically self-sufficient 119,000-dalton cytochrome P-450 monooxygenase induced by barbiturates in Bacillus Protein Engineering Of P450BM3 By Rational Redesign - 189 -megaterium.
  37. (1991). Characterization of recombinant Bacillus megaterium cytochrome P-450BM-3 and its two functional domains.
  38. (1988). Characterization of the protein expressed in Escherichia coli by a recombinant plasmid containing the Bacillus megaterium cytochrome P-450BM-3 gene.
  39. (1983). CHARMM: A program for macromolecular energy, minimization, and dynamics calculations.
  40. (1998). CHARMM: The energy function and its parameterization with an overview of Protein Engineering Of P450BM3 By Rational Redesign - 187 -the program. The Encyclopedia of Computational Chemistry.
  41. (2007). Co-expression of P450 BM3 and glucose dehydrogenase by recombinant Escherichia coli and its application in an NADPH-dependent indigo production system.
  42. (1989). Coding nucleotide, 5' regulatory, and deduced amino acid sequences of P-450BM-3, a single peptide cytochrome P-450:NADPH-P-450 reductase from Bacillus megaterium.
  43. (2004). Colorimetric high-throughput assay for alkene epoxidation catalyzed by cytochrome P450 BM-3 variant 139-3.
  44. (1988). Comparing the polarities of the amino acids: side-chain distribution coefficients between the vapor phase, cyclohexane, 1-octanol, and neutral aqueous solution.
  45. (2002). Comparison of the dynamics of substrate access channels in three cytochrome P450s reveals different opening mechanisms and a novel functional role for a buried arginine.
  46. (1996). Conformational dynamics in cytochrome P450-substrate interactions.
  47. (2007). Conformational dynamics of substrate in the active site of cytochrome P450 BM-3/NPG complex: Insights from NMR order parameters.
  48. (2007). Conformational dynamics of the cytochrome P450 BM3/N-Palmitoylglycine complex: The proposed "proximal-distal" transition probed by temperature-jump spectroscopy.
  49. (2006). Conformational equilibrium of cytochrome P450 BM-3 complexed with N-palmitoylglycine: A replica exchange molecular dynamics study.
  50. (1999). Controlled regioselectivity of fatty acid oxidation by whole cells producing cytochrome P450BM-3 monooxygenase under varied dissolved oxygen concentrations.
  51. (2004). Coot: model-building tools for molecular graphics. Acta Crystallographica. Section D:
  52. (1993). Critical residues involved in FMN binding and catalytic activity in cytochrome P450BM-3.
  53. (2001). Critical role of the residue size at position 87 in H2O2 - dependent substrate hydroxylation activity and H2O2 inactivation of cytochrome P450BM-3.
  54. (1995). Crystal Protein Engineering Of P450BM3 By Rational Redesign - 186 -structure of cytochrome P450cam complexed with its catalytic product, 5-exo-hydroxycamphor.
  55. (1993). Crystal structure of hemoprotein domain of P450BM-3, a prototype for microsomal P450's.
  56. (1997). Crystal structure of nitric oxide reductase from denitrifying fungus Fusarium oxysporum.
  57. (2004). Crystal structure of putidaredoxin reductase from Pseudomonas putida, the final structural component of the cytochrome P450cam monooxygenase.
  58. (1989). Crystal structure of the carbon monoxide-substrate-cytochrome P-450CAM ternary complex.
  59. (1991). Crystal structures of cytochrome P-450CAM complexed with camphane, thiocamphor, and adamantane: factors controlling P-450 substrate hydroxylation.
  60. (2003). Crystal structures of epothilone D-bound, epothilone B-bound, and substrate-free forms of cytochrome P450epoK.
  61. (2000). Crystal structures of ligand complexes of P450eryF exhibiting homotropic cooperativity.
  62. (2000). Cytochrome P450 3A9 catalyzes the metabolism of progesterone and other steroid hormones.
  63. (1998). Cytochrome P450 nomenclature
  64. (2002). Cytochrome P450(cin) (CYP176A), isolation, expression, and characterization.
  65. (2005). Cytochrome P450BM-3 mutants with improved catalytic properties of hydroxylating indole to indigo by error-prone PCR.
  66. (2005). Cytochrome P450s in plants. IN
  67. (2006). Cytochromes P450 as versatile biocatalysts.
  68. (2000). Cytochromes P450: a success story.
  69. (1996). Cytochromes P450: Structure, Function and Mechanism,
  70. (1997). Development and validation Protein Engineering Of P450BM3 By Rational Redesign - 184 -of a genetic algorithm for flexible docking.
  71. (2004). Developments in the CCP4 molecular-graphics project. Acta Crystallographica. Section D:
  72. (2005). Direct conversion of ethane to ethanol by engineered cytochrome P450 BM3.
  73. (2000). Directed evolution of the fatty-acid hydroxylase P450 BM-3 into an indole-hydroxylating catalyst. Chemistry -
  74. (1992). Domains of the catalytically self-sufficient cytochrome P-450 BM-3. Genetic construction, overexpression, purification and spectroscopic characterization.
  75. (1995). Dramatic differences in the motions of the mouth of open and closed cytochrome P450BM-3 by molecular dynamics simulations.
  76. (1993). Effect of fepradinol on rat hind paw oedema induced by several inflammatory agents.
  77. (1995). Effect of replacement of ferriprotoporphyrin IX in the haem domain of cytochrome P-450 BM-3 on substrate binding and catalytic activity.
  78. (2006). Effectiveness of low-dose Indinavir/Ritonavir at 400/100 mg twice a day with 2 nucleoside reverse transcriptase inhibitors in nonnucleoside reverse transcriptase inhibitor-experienced HIV-infected patients in India: 1-year follow-up.
  79. (1995). Electrocatalytically driven ω-hydroxylation of fatty acids using cytochrome P450 4A1.
  80. (2003). Electron transfer in flavocytochrome P450BM3: Kinetics of flavin reduction and oxidation, the role of cysteine 999, and relationships with mammalian cytochrome P450 reductase.
  81. (2005). Electron transfer partners of cytochrome P450.
  82. (1997). Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes.
  83. (2001). Engineering cytochrome P450 BM-3 for oxidation of polycyclic aromatic hydrocarbons.
  84. (2006). Engineering cytochrome P450 BM3 for terminal alkane hydroxylation.
  85. (1997). Engineering the substrate specificity of Bacillus megaterium cytochrome P-450 BM3: hydroxylation of alkyl trimethylammonium compounds.
  86. (1988). Enzymic hydrolysis of alkyl 3,4-epoxybutyrates. A new route to (R)-(-)-carnitine chloride.
  87. Evidence for its hemoprotein nature.
  88. (2002). Evidence for two different active oxygen species in cytochrome P450 BM3 mediated sulfoxidation and N-dealkylation reactions.
  89. (2008). Evolved CYP102A1 (P450(BM3)) variants oxidise a range of non-natural substrates and offer new selectivity options. Chemical Communications (Cambridge,
  90. (2008). Expression, activity and regulation of CYP3A in human and rodent brain.
  91. (1990). Fatty acid monooxygenation by cytochrome P-450BM-3.
  92. (1997). Fatty acid signals in Bacillus megaterium are attenuated by cytochrome P-450-mediated hydroxylation.
  93. (1977). Fatty acids of the genus Bacillus: an example of branched-chain preference.
  94. (2007). Filling a hole in cytochrome P450 BM3 improves substrate binding and catalytic efficiency.
  95. (2004). Flavocytochrome P450 BM3 mutant A264E undergoes substrate-dependent formation of a novel heme iron ligand set.
  96. (1999). Formation of indigo by recombinant mammalian cytochrome
  97. (2003). Haem-oxygen reactive intermediates: catalysis by the two-step.
  98. (1982). Heme ligand replacement reactions of cytochrome P-450. Protein Engineering Of P450BM3 By Rational Redesign - 197 -Characterization of the bonding atom of the axial ligand trans to thiolate as oxygen.
  99. (2005). Herbicide resistance in transgenic plants with mammalian P450 monooxygenase genes.
  100. (2007). Herbicide resistance of transgenic rice plants expressing human CYP1A1.
  101. (1987). High-resolution crystal structure of cytochrome P450cam.
  102. (1999). Homology modeling and substrate binding study of human CYP4A11 enzyme.
  103. (1999). How similar are P450s and what can their differences teach us?
  104. (2005). Human cytochrome P450 enzymes. IN
  105. (2005). Hydroxylation activity of P450 BM-3 mutant F87V towards aromatic compounds and its application to the synthesis of hydroquinone derivatives from phenolic compounds.
  106. (1998). hydroxylation regiospecificity and resistance to inactivation by 1-aminobenzotriazole.
  107. (1987). Identification and characterization of two functional domains in cytochrome P-450BM-3, a catalytically self-sufficient monooxygenase induced by barbiturates in Bacillus megaterium.
  108. (2002). Identification of a new class of cytochrome P450 from a Rhodococcus sp.
  109. (2007). Identification of critical residues in novel drug metabolizing mutants of cytochrome P450 BM3 using random mutagenesis.
  110. (2003). Improved protein-ligand docking using GOLD.
  111. (2005). Indole hydroxylation by bacterial cytochrome P450 BM-3 and modulation of activity by cumene hydroperoxide.
  112. (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.
  113. (1991). Iso- and anteiso-fatty acids in bacteria: biosynthesis, function, and taxonomic significance.
  114. (2002). Laboratory evolution of a soluble, self-sufficient, highly active alkane hydroxylase.
  115. (2004). Laboratory evolution of cytochrome P450 BM-3 monooxygenase for organic cosolvents.
  116. (2007). Laboratory evolution of P450 BM3 for mediated electron transfer yielding an activity-improved and reductase-independent variant.
  117. (1999). Laboratory evolution of peroxide-mediated cytochrome P450 hydroxylation.
  118. (2004). Likelihood-enhanced fast rotation functions.
  119. (2005). Likelihood-enhanced fast translation functions.
  120. (1978). Lipid and protein composition of membranes of Bacillus megaterium variants in the temperature range 5 to 70 degrees C.
  121. (1991). Long-term acetyl-L-carnitine treatment in Alzheimer's disease.
  122. (1994). Mechanism of anti-inflammatory action of fepradinol.
  123. (2001). Metabolic engineering of indene bioconversion in Rhodococcus sp.
  124. (1999). Microbial conversion of indene to indandiol: a key intermediate in the synthesis of CRIXIVAN.
  125. (1995). Modeling protein-substrate interactions in the heme domain of cytochrome P450BM-3.
  126. (2001). Modification of the fatty acid specificity of cytochrome P450 BM-3 from Bacillus megaterium by directed evolution: a validated assay.
  127. (2002). Molecular and biochemical characterization of two P450 enzymes in the ecdysteroidogenic pathway of Drosophila melanogaster.
  128. (1999). Molecular modelling of CYP4A subfamily members based on sequence homology with CYP102.
  129. (1995). Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation.
  130. (1977). NADPH-cytochrome P-450 reductase from rat liver: purification by affinity chromatography and characterization.
  131. (1999). Nature's universal oxygenases: the cytochromes P450.
  132. (2005). Nitric oxide reductase (P450nor) from Fusarium oxysporum.
  133. (1992). Nomenclature Committee of the International Union of Biochemistry (NC-IUB). Nomenclature of electron-transfer proteins. Recommendations
  134. (2005). Observation of ligand binding to cytochrome P450 BM-3 by means of solid-state NMR spectroscopy.
  135. Of P450BM3 By Rational Redesign -
  136. (2000). Oxidation of indole by cytochrome P450 enzymes.
  137. (2003). Oxygen activation and electron transfer in flavocytochrome P450 BM3.
  138. (1997). Oxygen activation by cytochrome P450BM-3: Effects of mutating an active site acidic residue
  139. (2002). P450 BM3: the very model of a modern flavocytochrome.
  140. (2000). P450 in biotechnology: zinc driven ω-hydroxylation of p-nitrophenoxydodecanoic acid using P450 BM-3 F87A as a catalyst.
  141. (1999). P450 monooxygenase in biotechnology. I. Single-step, large-scale purification method for cytochrome P450 BM-3 by anion-exchange chromatography.
  142. (1996). P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature.
  143. (1991). P450BM-3 and other inducible bacterial P450 cytochromes: Biochemistry and regulation.
  144. (1985). P450cam gene cloning and expression in Pseudomonas putida and Escherichia coli.
  145. (1996). P450s: structural similarities and functional differences.
  146. (1998). Parametrization of aliphatic CHn united atoms of GROMOS96 force field.
  147. (2004). Phe393 mutants of cytochrome P450 BM3 with modified heme redox potentials have altered heme vinyl and propionate conformations.
  148. (2001). Phenylalanine 393 exerts thermodynamic control over the heme of flavocytochrome P450 BM3.
  149. (2001). Pivotal role of water in the mechanism of P450BM-3.
  150. (2007). PksS from Bacillus subtilis is a cytochrome P450 involved in bacillaene metabolism.
  151. (2006). Plant cytochrome P450-mediated herbicide metabolism.
  152. (1993). PROCHECK: a program to check the stereochemical quality of protein structures.
  153. (2001). Protein engineering of Bacillus megaterium CYP102.
  154. (2000). Proton delivery in NO reduction by fungal nitric-oxide reductase. Cryogenic crystallography, spectroscopy, and kinetics of ferric-NO complexes of wild-type and mutant enzymes.
  155. (1993). Purification schemes for the constituent domains of cytochrome P450
  156. (2001). Random mutagenesis of human cytochrome P450 2A6 and screening with indole oxidation products.
  157. (2001). Rational evolution of a medium chain-specific cytochrome P-450 BM-3 variant.
  158. (2000). Rational re-design of the substrate binding site of flavocytochrome P450 BM3.
  159. (2006). Recent advances in oxygenase-catalyzed biotransformations.
  160. (1992). Recent changes to the MOSFLM package for processing film and image plate data.
  161. (2003). Recombinant Saccharomyces cerevisiae expressing P450 in artificial digestive systems: a model for biodetoxication in the human digestive environment.
  162. (1997). Redox control of the catalytic cycle of flavocytochrome P-450 BM3.
  163. (2003). Regio- and enantioselective alkane hydroxylation with engineered cytochromes P450 BM-3.
  164. (2002). Regioselective peroxo-dependent heme alkylation in P450BM3-F87G by aromatic aldehydes: effects of alkylation on catalysis.
  165. (2002). Regioselectivity and activity of cytochrome P450 BM-3 and mutant F87A in reactions driven by hydrogen peroxide.
  166. (1993). Regulation of fatty acid biosynthesis in Escherichia coli.
  167. (1984). Regulation of ribosomal RNA promoters with a synthetic lac operator.
  168. (2001). Residue size at position 87 of cytochrome P450 BM-3 determines its stereoselectivity in propylbenzene and 3-chlorostyrene oxidation.
  169. (1999). Roles of key active-site residues in flavocytochrome P450 BM3.
  170. (2006). Selective hydroxylation of highly branched fatty acids and their derivatives by CYP102A1 from Bacillus megaterium.
  171. (2005). Sensitive assay for laboratory evolution of hydroxylases toward aromatic and heterocyclic compounds.
  172. (1967). Spectral studies of drug interaction with hepatic microsomal cytochrome.
  173. (2004). Steepest descent with momentum for quadratic functions is a version of the conjugate gradient method.
  174. (1989). Stereochemical control of yeast reductions: Synthesis of R-(+)-alpha-lipoic acid.
  175. (2005). Stereoselective hydroxylation of an achiral cyclopentanecarboxylic acid derivative using engineered P450s BM-3.
  176. (1986). Streptomycin accumulation by Bacillus subtilis requires both a membrane potential and cytochrome aa3. Antimicrobial Agents and
  177. (2007). Structural analysis of CYP2R1 in complex with vitamin D3.
  178. (2001). Structural and spectroscopic analysis of the F393H mutant of flavocytochrome P450 BM3.
  179. (2007). Structural and spectroscopic characterization of P450 BM3 mutants with unprecedented P450 heme iron ligand sets
  180. (2004). Structural aspects of ligand binding to and electron transfer in bacterial and fungal P450s.
  181. (2006). Structural basis for ligand promiscuity in cytochrome
  182. (2001). Structural determinants of active site binding affinity and metabolism by cytochrome P450 BM-3.
  183. (2004). Structural evidence for direct hydride transfer from NADH to cytochrome P450nor.
  184. (1999). Structure of a cytochrome P450-redox partner electron-transfer complex.
  185. (1995). Structure of cytochrome P450eryf involved in erythromycin biosynthesis.
  186. (2005). Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen.
  187. (1992). Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences.
  188. (1993). Substrate specificity of 6-deoxyerythronolide B hydroxylase, a bacterial cytochrome P450 of erythromycin A biosynthesis.
  189. (1974). Superoxide anion production by the autoxidation of cytochrome P450cam.
  190. (1997). SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling.
  191. (2005). Switching pyridine nucleotide specificity in P450 BM3: Mechanistic analysis of the W1046H and W1046A enzymes.
  192. (1985). The 2.6-Å crystal structure of Pseudomonas putida cytochrome P-450.
  193. (1964). The carbon monoxide-binding pigment of liver microsomes I.
  194. (1964). The carbon monoxide-binding pigment of liver microsomes II.
  195. (1996). The catalytic mechanism of cytochrome P450 BM3 involves a 6 Å movement of the bound substrate on reduction.
  196. (2000). The catalytic pathway of cytochrome P450cam at atomic resolution.
  197. (1994). The CCP4 suite: programs for protein crystallography. Acta Crystallographica. Section D:
  198. (2005). The diversity and importance of microbial cytochromes P450. IN
  199. (2006). The efficiency of recombinant Escherichia coli as biocatalyst for stereospecific epoxidation.
  200. (1996). The highly stereoselective oxidation of polyunsaturated fatty acids by cytochrome P450BM-3.
  201. (2000). The protein data bank.
  202. (2007). The Q403K mutant heme domain of flavocytochrome P450
  203. (1972). The role of putidaredoxin and P450 cam in methylene hydroxylation.
  204. (2008). The role of the conserved threonine in P450 BM3 oxygen activation: substrate-determined hydroxylation activity of the Thr268Ala mutant.
  205. (1995). The role of Thr268 in oxygen activation of cytochrome P450BM-3.
  206. (1994). The role of tryptophan 97 of cytochrome P450 BM3 from Bacillus megaterium in catalytic function. Evidence against the 'covalent switching' hypothesis of P-450 electron transfer.
  207. (1999). The Rossmann Fourier autoindexing algorithm in MOSFLM.
  208. (2004). The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-Å resolution.
  209. (1997). The structure of the cytochrome P450BM-3 haem domain complexed with the fatty acid substrate, palmitoleic acid.
  210. (1945). The structures of the bromodioxindoles of Baeyer and Knop.
  211. (1991). The surface-exposed tyrosine residue Tyr83 of pea plastocyanin is involved in both binding and electron transfer reactions with cytochrome f.
  212. (1983). The tac promoter: a functional hybrid derived from the trp and lac promoters.
  213. (1996). The ω-hydroxlyation of lauric acid: oxidation of 12-hydroxlauric acid to dodecanedioic acid by a purified recombinant fusion protein containing P450 4A1 and NADPH-P450 reductase.
  214. (2005). Thermal equilibrium of high- and low-spin forms of cytochrome P450 BM-3: Repositioning of the substrate?
  215. (2003). Thermostabilization of a cytochrome P450 peroxygenase.
  216. (1998). Thr268 in substrate binding and catalysis in P450BM-3.
  217. (1997). Three-dimensional structure of NADPH-cytochrome P450 reductase: prototype for FMN- and FAD-containing enzymes.
  218. (1998). Towards a biocatalyst for (S)-styrene oxide production: characterization of the styrene degradation pathway of Pseudomonas sp. strain VLB120.
  219. (1995). Transcriptional regulation of the genes encoding cytochromes P450BM-1 and P450BM-3 in Bacillus megaterium by the binding of Bm3R1 repressor to Barbie box elements and operator sites.
  220. (1995). Twenty-five years of P450cam research: Mechanistic insights into oxygenase catalysis.
  221. (2007). Understanding a mechanism of organic cosolvent inactivation in heme monooxygenase P450 BM-3.
  222. (1998). US drug and biologic approvals in
  223. (1996). VMD: visual molecular dynamics.
  224. (2007). Wild-type CYP102A1 as a biocatalyst: turnover of drugs usually metabolised by human liver enzymes.
  225. (2006). with the antifungal drug bifonazole: insight into P450 conformational plasticity and membrane interaction.
  226. (1975). ω-1, ω-2 and ω-3 hydroxylation of long-chain fatty acids, amides and alcohols by a soluble enzyme system from Bacillus megaterium.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.